Home
About
Services
Partners
Client Portfolio
News
Contact
Blackstone turns up heat on hotelier Unizo with tender offer
October 15, 2019
Exclusive: Deutsche Bank took years to flag suspect Danske money flows – source
October 15, 2019
0
J&J bumps up full-year profit view on strength of cancer drugs
Published by
Muller&Green
at
October 15, 2019
Categories
RSS
Tags
Johnson & Johnson on Tuesday boosted its full-year adjusted profit forecast, as multi-billion dollar sales of its cancer drugs Darzalex and Imbruvica helped it beat estimates for third-quarter profit.
Powered by
WPeMatico
Muller&Green
Related posts
June 18, 2020
Chanel warns virus impact will linger on luxury sector
Read more
June 18, 2020
IMF says deeper-than-expected contraction in U.S. economy likely in second quarter
Read more
June 18, 2020
Prudential sells Jackson equity stake to Apollo-backed Athene for $500 million
Read more